Related Experiment Videos
Effect of D-glucitol-hexanicotinate on platelet aggregability in patients with coronary heart disease
Insights
D-glucitol-hexanicotinate (sorbinicate) effectively reduced platelet aggregation in male myocardial infarction survivors. This lipid-lowering agent shows promise for preventing atherosclerotic diseases.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Myocardial infarction survivors are at high risk for recurrent cardiovascular events.
- Platelet aggregation plays a critical role in the pathogenesis of atherosclerosis and thrombosis.
Purpose of the Study:
- To evaluate the anti-aggregating effects of D-glucitol-hexanicotinate (sorbinicate) in patients with a history of myocardial infarction.
- To assess the lipid-lowering properties of sorbinicate.
Main Methods:
- A daily dose of 1.6 mg of sorbinicate was administered to 16 male patients post-myocardial infarction.
- Platelet aggregation was measured using collagen, ADP, and epinephrine as agonists.
- A control group of 13 comparable patients did not receive sorbinicate.
Main Results:
- Sorbinicate significantly decreased platelet aggregation induced by collagen, ADP, and epinephrine after 3 months.
- The control group showed a significant increase in platelet aggregation induced by ADP and epinephrine.
- Sorbinicate demonstrated effective lipid-lowering activity.
Conclusions:
- D-glucitol-hexanicotinate (sorbinicate) possesses significant anti-platelet aggregation properties.
- The combined hypolipidemic and anti-aggregating effects of sorbinicate may be beneficial for preventing atherosclerotic disease.
- Sorbinicate holds potential for both primary and secondary prevention strategies in cardiovascular disease.
Abstract:
D-glucitol-hexanicotinate (sorbinicate) was administered at a daily dose of 1.6 mg to 16 male patients who had survived myocardial infarction. Platelet aggregation induced by collagen (5 micrograms/ml), by ADP (2, 1.2, 0.8, and 0.4 X 10(-6)M), and by epinephrine (1 and 0.5 X 10(-6)M) was significantly decreased after 3 months of therapy. In a group of 13 comparable patients, who did not receive sorbinicate, platelet aggregation induced by ADP (1.2, 0.8, and 0.4 X 10(-6)M) and by epinephrine (1 X 10(-5)M and 1 X 10(-6)M) was significantly increased 3 months after entry into the study. Sorbinicate has effective lipid-lowering activity; the combination of hypolipidemic and anti-aggregating properties may prove important in primary and secondary prevention of atherosclerotic disease.